| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.44 | 0.05 (+2.09%) | 2.14 - 4.77 | 227.2 thousand (Below Avg) |
Market data as of 1:16PM 05/20/13. Quotes are delayed by at least 15 min.
| Open | 2.39 |
|---|---|
| Previous Close | 2.39 |
| Day's Range | 2.39 - 2.45 |
| Market Cap | 291.8M |
| Avg Volume (10 Day) | 685.0K |
| Price/Earnings (Trailing 12 Mo.) | 23.0x |
| Earnings Per Share (Trailing 12 Mo.) | 0.12 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion
Business Wire - Wednesday 05/15/2013 4:30 PM ET
Navidea Biopharmaceuticals Announces First Quarter 2013 Results
Business Wire - Wednesday 05/08/2013 7:00 AM ET
Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013
Business Wire - Friday 05/03/2013 11:55 AM ET
Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®
Business Wire - Wednesday 05/01/2013 7:00 AM ET
Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference
Business Wire - Thursday 04/25/2013 2:51 PM ET
Navidea Biopharmaceuticals Announces Underwritten Sale of Common Stock
Business Wire - Wednesday 04/24/2013 8:45 AM ET
| NAVB | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -98.07% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | 4.35% | |
| Price/Sales | 4277.86 |
| Company | Last | Change |
|---|---|---|
| Palomar Medical Technologies Inc | 13.45 | -0.81% |
| Syneron Medical Ltd | 8.95 | +0.45% |
| RTI Biologics Inc | 4.37 | +0.92% |
| Exactech Inc | 18.21 | +1.17% |
| PhotoMedex Inc | 16.50 | +2.29% |
Data is delayed by at least 15 min.